MAPT and Atrophy: In Tau-P301S (PS19) transgenic mice, treatment after disease onset with salsalate, a small-molecule anti-inflammatory agent that precedes the FDA approval process, reduced tau acetylation at Lys174, decreased aggregation, prevented hippocampal atrophy, and rescued memory deficits in the mice [79].